See more : CSMall Group Limited (1815.HK) Income Statement Analysis – Financial Results
Complete financial analysis of RedHill Biopharma Ltd. (RDHL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RedHill Biopharma Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Develop Global Limited (DVP.AX) Income Statement Analysis – Financial Results
- Moriya Transportation Engineering and Manufacturing Co.,Ltd. (6226.T) Income Statement Analysis – Financial Results
- CynergisTek, Inc. (CTEK) Income Statement Analysis – Financial Results
- Mie Kotsu Group Holdings, Inc. (3232.T) Income Statement Analysis – Financial Results
- Kinovo plc (KINO.L) Income Statement Analysis – Financial Results
RedHill Biopharma Ltd. (RDHL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.redhillbio.com
About RedHill Biopharma Ltd.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.51M | 61.80M | 85.76M | 64.36M | 6.29M | 8.36M | 4.01M | 101.00K | 3.00K | 7.01M | 12.00K | 16.00K | 23.00K | 0.00 |
| Cost of Revenue | 3.46M | 33.34M | 49.41M | 36.89M | 2.26M | 2.84M | 2.13M | 30.54M | 22.00M | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.05M | 28.46M | 36.35M | 27.47M | 4.03M | 5.52M | 1.88M | -30.44M | -22.00M | 5.96M | 12.00K | 16.00K | 23.00K | 0.00 |
| Gross Profit Ratio | 46.89% | 46.06% | 42.39% | 42.68% | 64.09% | 66.06% | 46.94% | -30,140.59% | -733,300.00% | 85.03% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 3.52M | 7.28M | 29.50M | 16.49M | 17.42M | 24.86M | 32.97M | 25.24M | 17.77M | 12.70M | 8.10M | 6.46M | 5.41M | 736.00K |
| General & Administrative | 28.88M | 54.97M | 76.60M | 25.38M | 11.48M | 7.51M | 8.03M | 5.40M | 4.13M | 4.01M | 2.68M | 2.60M | 2.48M | 518.00K |
| Selling & Marketing | 2.10M | 9.06M | 11.39M | 49.29M | 18.33M | 12.49M | 12.01M | 1.56M | 1.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.98M | 64.03M | 87.99M | 74.66M | 29.81M | 19.99M | 20.04M | 5.40M | 4.13M | 4.01M | 2.68M | 2.60M | 2.48M | 518.00K |
| Other Expenses | -44.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 845.00K | 0.00 | 100.00K | -100.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -9.56M | 71.31M | 117.49M | 91.15M | 47.23M | 44.85M | 53.85M | 30.64M | 22.01M | 16.61M | 10.78M | 9.06M | 7.90M | 1.73M |
| Cost & Expenses | -6.10M | 104.64M | 166.89M | 128.04M | 49.49M | 47.69M | 55.98M | 30.64M | 22.01M | 17.66M | 10.78M | 9.06M | 7.90M | 1.73M |
| Interest Income | 93.76K | 140.00K | 51.00K | 270.00K | 1.34M | 678.00K | 6.51M | 1.55M | 1.12M | 319.00K | 158.00K | 119.00K | 14.00K | 2.00K |
| Interest Expense | 367.00K | 41.33M | 16.57M | 12.76M | 438.00K | 167.00K | 77.00K | 375.00K | 212.00K | 383.00K | 14.00K | 1.48M | 65.00K | 876.00K |
| Depreciation & Amortization | 1.99M | 8.12M | 18.16M | 8.81M | 1.22M | 89.71K | 81.57K | 44.14K | 36.00K | 27.00K | 24.00K | 24.00K | 15.00K | -63.00K |
| EBITDA | 26.31M | -42.84M | -63.03M | -54.94M | -40.78M | -38.60M | -45.79M | -30.50M | -21.87M | -10.62M | -10.75M | -9.02M | -7.86M | -2.55M |
| EBITDA Ratio | 403.94% | -56.00% | -73.46% | -84.94% | -646.21% | -461.28% | -1,132.67% | -28,664.36% | -694,733.33% | -146.86% | -88,250.00% | -56,837.50% | -36,456.52% | 0.00% |
| Operating Income | 12.63M | -42.84M | -81.14M | -63.68M | -43.20M | -39.33M | -51.97M | -30.54M | -22.00M | -10.65M | -10.77M | -9.04M | -7.87M | -1.73M |
| Operating Income Ratio | 193.95% | -69.33% | -94.61% | -98.95% | -686.71% | -470.47% | -1,297.03% | -30,240.59% | -733,400.00% | -151.80% | -89,766.67% | -56,500.00% | -34,230.43% | 0.00% |
| Total Other Income/Expenses | 11.32M | -28.83M | -16.61M | -12.49M | 897.00K | 511.00K | 6.43M | 1.17M | 812.00K | -64.00K | 144.00K | -1.29M | -7.63M | -811.00K |
| Income Before Tax | 23.95M | -71.67M | -97.74M | -76.17M | -42.30M | -38.82M | -45.54M | -29.37M | -21.09M | -10.71M | -10.63M | -10.33M | -15.50M | -2.54M |
| Income Before Tax Ratio | 367.75% | -115.97% | -113.98% | -118.36% | -672.45% | -464.35% | -1,136.61% | -29,079.21% | -703,000.00% | -152.71% | -88,566.67% | -64,537.50% | -67,404.35% | 0.00% |
| Income Tax Expense | 0.00 | -12.42M | 16.57M | 12.84M | 1.33M | 727.00K | 6.29M | 1.27M | 900.00K | 222.00K | 142.00K | 1.29M | 7.63M | 874.00K |
| Net Income | 23.92M | -59.25M | -114.31M | -89.02M | -43.63M | -38.82M | -45.54M | -29.37M | -21.09M | -10.71M | -10.63M | -10.33M | -15.50M | -2.54M |
| Net Income Ratio | 367.19% | -95.87% | -133.30% | -138.31% | -693.59% | -464.35% | -1,136.61% | -29,079.21% | -703,000.00% | -152.71% | -88,566.67% | -64,537.50% | -67,404.35% | 0.00% |
| EPS | 3.69 | -38.27 | -98.27 | -97.75 | -58.78 | -68.00 | -104.00 | -94.96 | -76.13 | -49.47 | -68.15 | -80.00 | -128.96 | -19.35 |
| EPS Diluted | 3.69 | -38.27 | -98.27 | -97.75 | -58.78 | -68.00 | -104.00 | -92.00 | -75.51 | -49.12 | -68.15 | -78.53 | -128.96 | -19.35 |
| Weighted Avg Shares Out | 6.48M | 1.55M | 1.16M | 910.69K | 742.30K | 570.88K | 437.92K | 309.30K | 277.04K | 216.53K | 155.95K | 129.08K | 120.22K | 131.49K |
| Weighted Avg Shares Out (Dil) | 6.48M | 1.55M | 1.16M | 910.69K | 742.30K | 570.88K | 437.92K | 319.24K | 279.29K | 218.06K | 155.95K | 131.49K | 120.22K | 131.49K |
The Impact of Market Trends on Penny Stocks Performance
Why Is Redhill Biopharma (RDHL) Stock Up 32% Today?
RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease
RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19
Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL)
RedHill Biopharma Closes $8.0 Million Underwritten Public Offering
RedHill Biopharma Prices $8.0 Million Underwritten Public Offering
RedHill Biopharma Announces Proposed Public Offering
RedHill Biopharma Announces Q3/22 Results and Operational Highlights
RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury
Source: https://incomestatements.info
Category: Stock Reports